Chapter 1: Executive Summary

Background
Scope and Methodology
Size and Growth of Market
Market Trends
The Nature of the Industry
The New Technologies

Chapter 2: Introduction

Background
Pathology
• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes

Long-Term Complications
• Hypertension
• Dyslipidemia
• Cardiovascular Disease
• Vascular Complications
• Diabetic Retinopathy
• Renal Complications
• Neuropathies
• Diabetic Foot

Epidemiology
• United States
• France
• Germany
• Italy
• Japan
• Spain
• United Kingdom

Chapter 3: Diabetes Monitoring

Background
Glucose Monitoring
• Glucose
• Hemoglobin A1c

Microalbumin

Chapter 4: Current Therapeutic Approaches

Background
Therapeutic Practices
• United States
• France
• Germany
• Italy
• Japan
• Spain
• United Kingdom

Current Therapeutics for Diabetes
• Insulins
• Oral Hypoglycemics

Current Therapeutics for Diabetic Complications
• Antihypertensive Therapy
• Dyslipidemia Therapy
• Atherosclerosis Therapy
• Peripheral Vascular Disease Therapy

Chapter 5: Diabetes Monitoring and Therapeutics Markets

Market Status and Segmentation
Market Trends
• United States
• France
• Germany
• Italy
• Japan
• Spain
• United Kingdom

Chapter 6: Forward-Looking Technologies

Recent Research
• Prevention
• Insulin
• Hypoglycemic Agents

Insulin Pumps
Inhaled Insulin
Oral Insulin
Gene Therapy
Transplantation

Chapter 7: Company Profiles

Abbott Laboratories
Abgenix, Inc.
Alkermes
Amylin Pharmaceuticals
AstraZeneca
Aventis Pharma US Division of Aventis
The Bayer Group (USA) Subsidiary of Bayer AG
BresaGen Limited
Bristol-Myers Squibb
Calyx Therapeutics Inc.
Cygnus, Inc.
Diabetogen Biosciences, Inc.
GlaxoSmithKline
Lexicon Genetics Inc.
Eli Lilly & Co.
Metabolex, Inc.
MitoKor
Neurocrine Biosciences
Novo Nordisk
O.S.I. Pharmaceuticals
Pfizer Inc.
Takeda Pharmaceuticals
Telik, Inc.
Transition Therapeutics, Inc.

Chapter 8: Conclusions and Strategic Implications

Public Health Recognition
The Pre-eminence of Insulin
Movement Away from Injection
Drug Discovery and Innovation
Insulin and Type 2
Unmet Need in the Type 2 Market
Expansion of Type 2 vs Type 1 Markets
Number of Competitors
Fate of Finger-Stick Testing
Timing of New Product Introductions
Future of Diabetic Complications

List of Exhibits
Table 1-1: Market for Insulin in the Seven Major World Healthcare Markets, 1999-2007
Table 1-2: Market for Oral Hypoglycemics in the Seven Major World Healthcare Markets, 1999-2007
Table 1-3: Market for Drugs to Treat Diabetic Complications in the Major World Healthcare Markets, 1999-2007
Table 2-1: Characteristics of Type 1 and Type 2 Diabetes Mellitus
Table 2-2: Common Symptoms and Conditions of Diabetes Mellitus
Table 2-3: Prevalence Rates for Diagnosed Type 1 and Type 2 Diabetes Mellitus in the Seven Major World Healthcare Markets, 1999-2007
Table 2-4: Diagnosed Diabetes Population for the Seven Major World Healthcare Markets, 1999-2007
Table 3-1: Key Glucose Monitoring Products on the Market
Table 3-2: Key Ketone Monitoring Products on the Market
Table 4-1: Estimated Number of Preventable Diabetes Cases and Complications in the United States
Table 4-2: Insulin Products for the Treatment of Type 1 Diabetes
Table 4-3: Drugs in Development for the Treatment of Type 1 Diabetes
Table 4-4: Oral Hypoglycemics for the Treatment of Type 2 Diabetes
Table 4-5: Drugs in Clinical Development for the Treatment of Type 2 Diabetes
Table 4-6: Common ACE Inhibitors on the Market for Diabetic Hypertension
Table 4-7: Common Adrenergic Receptors on the Market for Diabetic Hypertension
Table 4-8: Common Calcium Channel Blockers on the Market for Diabetic Hypertension
Table 4-9: Common Combined Diuretic Products on the Market for Diabetic Hypertension
Table 4-10: Common Angiotensin II Receptor Antagonists on the Market for Diabetic Hypertension
Table 4-11: Commonly Used Anti-Lipemic Agents on the Market for Diabetic Dyslipidemia
Table 4-12: Vaughn Williams Classification of Anti-Arrhythmic Drugs
Table 4-13: Currently Marketed Anti-Arrhythmatic Drugs
Table 4-14: Drugs Used to Combat Diabetic Peripheral Vascular Disease
Table 4-14: Drugs Used to Combat Diabetic Peripheral Vascular Disease
Table 5-2: Estimated Market Sizes for Insulin in the Seven Major World Healthcare Markets, 1999-2007
Table 5-3: Estimated Market Sizes for Oral Hypoglycemics in the Seven Major World Healthcare Markets, 1999-2007
Table 5-4: Estimated Market Sizes for Drugs to Treat Diabetic Complications in the Seven Major World Healthcare Markets, 1999-2007
Table 5-5: Estimated Diabetes-Care Market Size in the United States, 1999-2007
Table 5-6: Estimated Diabetes-Care Market Size in France, 1999-2007
Table 5-7: Estimated Diabetes-Care Market Size in Germany, 1999-2007
Table 5-8: Estimated Diabetes-Care Market Size in Italy, 1999-2007
Table 5-9: Estimated Diabetes-Care Market Size in Japan, 1999-2007
Table 5-10: Estimated Diabetes-Care Market Size in Spain, 1999-2007
Table 5-11: Estimated Diabetes-Care Market Size in the United Kingdom, 1999-2007
Figure 1-1: Diagnosed and Undiagnosed Diabetes Cases in the Major World Healthcare Markets, 1999-2007
Figure 1-2: Trending in the Major Blood Glucose Monitoring Markets, 1999-2007
Figure 2-1: Diagnosed and Undiagnosed Diabetes Cases in the Seven Major World Healthcare Markets, 1999-2007
Figure 2-2: Composition of the Diagnosed Diabetes Patient Population in the Seven Major World Healthcare Markets, 2001 and 2007
Figure 2-3: Geographic Distribution of the Diagnosed Diabetes Patient Population, 2001
Figure 2-4: Geographic Distribution of the Diagnosed , Type 1 Diabetes Patient Population, 2001
Figure 2-5: Geographic Distribution of the Diagnosed Type 2 Diabetes Patient Population: 2001
Figure 2-6: General Population Distribution for the Seven Major World Healthcare Markets, 2001
Figure 2-7: Historic and Forecast Diagnosed Diabetes Cases in the United States, 1999-2007
Figure 2-8: Historic and Forecast Diagnosed Diabetes Cases in France, 1999-2007
Figure 2-9: Historic and Forecast Diagnosed Diabetes Cases in Germany, 1999-2007
Figure 2-10: Historic and Forecast Diagnosed Diabetes in Italy, 1999-2007
Figure 2-11: Historic and Forecast Diagnosed Diabetes in Japan, 1999-2007
Figure 2-12: Historic and Forecast Diagnosed Diabetes in Spain, 1999-2007
Figure 2-13: Historic and Forecast Diagnosed Diabetes in the United Kingdom, 1999-2007
Figure 5-1: Trending in the World’s Major Blood Glucose Monitoring Markets, 1999-2007
Figure 5-2: Distribution of the Blood Glucose Monitoring Markets by Country
Figure 5-3: Market Shares of the Key Participants in the Major World Markets for Glucose Monitoring Products, 2001
Figure 5-4: Trending in the World’s Major Markets for Insulin, 1999-2007
Figure 5-5: Market Distribution in the World’s Major Markets for Insulin, 1999-2007
Figure 5-6: Estimated Insulin Market Shares in the Seven Major World Healthcare Markets, 2001
Figure 5-7: Trending in the World’s Major Markets for Oral Hypoglycemic Drugs, 1999-2007
Figure 5-8: Market Distribution in the World’s Major Markets for Oral Hypoglycemics, 1999-2007
Figure 5-9: Estimated Oral Hypoglycemic Drug Market Shares in the Seven Major World Healthcare Markets, 2001
Figure 5-10: Trending in the Total World’s Major Markets for Drugs to Treat Diabetic Complications by Complication, 1999-2007
Figure 5-11: Composition of the Total World’s Major Markets for Drugs to Treat Diabetic Complications by Complication, 1999-2007
Figure 5-12: Trending in the United States Market for Diabetes-Care Products by Product Class, 1999-2007
Figure 5-13: Composition of the United States Market for Diabetes-Care Products by Product Class, 1999-2007
Figure 5-14: Trending in the French Market for Diabetes-Care Products by Product Class, 1999-2007
Figure 5-15: Composition of the French Market for Diabetes-Care Products by Product Class, 1999-2007
Figure 5-16: Trending in the German Market for Diabetes-Care Products by Product Class, 1999-2007
Figure 5-17: Composition of the German Market for Diabetes-Care Products by Product Class, 1999-2007
Figure 5-18: Trending in the Italian Market for Diabetes-Care Products by Product Class, 1999-2007
Figure 5-19: Composition of the Italian Market for Diabetes-Care Products by Product Class, 1999-2007
Figure 5-20: Trending in the Japanese Market for Diabetes-Care Products by Product Class, 1999-2007
Figure 5-21: Composition of the Japanese Market for Diabetes-Care Products by Product Class, 1999-2007
Figure 5-22: Trending in the Spanish Market for Diabetes-Care Products by Product Class, 1999-2007
Figure 5-23: Composition of the Spanish Market for Diabetes-Care Products by Product Class, 1999-2007
Figure 5-24: Trending in the United Kingdom Market for Diabetes-Care Products by Product Class, 1999-2007
Figure 5-25: Composition of the United Kingdom Market for Diabetes-Care Products by Product Class, 1999-2007